BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is projected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $1.24 billion for the quarter.

BioNTech Stock Up 4.7 %

BNTX stock opened at $114.77 on Thursday. The company’s 50 day simple moving average is $117.07 and its 200-day simple moving average is $112.47. The firm has a market capitalization of $27.51 billion, a PE ratio of -54.65 and a beta of 0.30. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

Analysts Set New Price Targets

Several analysts have recently commented on BNTX shares. Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. Wells Fargo & Company started coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target on the stock. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Finally, Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.